Studies that employed neutralizing antibodies against VEGFR3 showed reduced tumor-associated lymphatic formation, tumor growth, and lymph node metastasis in mice [91,92,93]; however, monotherapy using a humanized monoclonal anti-VEGFR3 (LY3022856) in a phase I clinical trial of 44 patients showed minimal anti-tumor activity as measured by radiographic response [94]. Here, FLT4 is linked to neoplasm.